



Q2 2023 Financial Results

Appendix



Anylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	Three Months Ended	
	June 30, 2023	June 30, 2022
Reconciliation of GAAP to Non-GAAP research and development:		
GAAP research and development	\$ 248,526	\$ 205,712
Less: Stock-based compensation expenses	(32,801)	(10,638)
Non-GAAP research and development	<u>\$ 215,725</u>	<u>\$ 195,074</u>
Reconciliation of GAAP to Non-GAAP selling, general and administrative:		
GAAP selling, general and administrative	\$ 214,689	\$ 169,984
Less: Stock-based compensation expenses	(43,001)	(19,833)
Non-GAAP selling, general and administrative	<u>\$ 171,688</u>	<u>\$ 150,151</u>
Reconciliation of GAAP to Non-GAAP operating loss:		
GAAP operating loss	\$ (229,831)	\$ (191,686)
Add: Stock-based compensation expenses	75,802	30,471
Non-GAAP operating loss	<u>\$ (154,029)</u>	<u>\$ (161,215)</u>



Anylam Pharmaceuticals, Inc.

Reconciliation of Revenue and Growth at Constant Currency

	Three Months Ended June 30, 2023
Total TTR net product revenue growth, as reported	46 %
Add: Impact of foreign currency translation	1
Total TTR net product revenue growth at constant currency	<u>47 %</u>
Total Ultra Rare net product revenue growth, as reported	37 %
Add: Impact of foreign currency translation	—
Total Ultra Rare net product revenue growth at constant currency	<u>37 %</u>
Total net product revenue growth, as reported	43 %
Add: Impact of foreign currency translation	1
Total net product revenue growth at constant currency	<u>44 %</u>
Total revenue growth, as reported	42 %
Add: Impact of foreign currency translation	1
Total revenue growth at constant currency	<u>43 %</u>